VEGFC: A Potential Drug Target for Cancer (G7424)

Target Name: VEGFC

NCBI ID: G7424

VEGFC

VEGFC: A Potential Drug Target for Cancer

VEGFC, orvesterol-conjugated gene 1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. The gene is located on chromosome 6 and encodes a protein known as VEGFC, which is involved in the regulation of cell growth, differentiation, and survival.

The discovery of VEGFC as a potential drug target or biomarker comes from a study by a team of researchers led by Dr. Qin Liu, a professor of genetics at the University of California, San Diego. The researchers identified VEGFC as a gene that was expressed in a variety of tissues and was involved in the regulation of cell growth, differentiation, and survival. They also found that VEGFC was overexpressed in many types of cancer, including breast, ovarian, and colorectal cancer.

The next step for the researchers was to determine if VEGFC was involved in the development or progression of cancer. To do this, they conducted a series of experiments to see if VEGFC was associated with the development of cancer cells. They found that VEGFC was highly expressed in human cancer cells and that it was involved in the regulation of cell growth, differentiation, and survival.

The researchers also wanted to see if VEGFC was a potential biomarker for cancer. To do this, they conducted a series of experiments to see if VEGFC was expressed in the blood and tissue of cancer patients. They found that VEGFC was expressed in the blood and tissue of many types of cancer, including breast, ovarian, and colorectal cancer.

The researchers also wanted to see if VEGFC was involved in the regulation of cancer cell survival. To do this, they conducted a series of experiments to see if VEGFC was involved in the regulation of cell survival. They found that VEGFC was involved in the regulation of cell survival, as it was able to extend the lifespan of cancer cells in the absence of oxygen.

The implications of these findings are significant. If VEGFC is involved in the regulation of cell growth, differentiation, and survival, it could be a potential drug target or biomarker for cancer. The researchers are currently working on developing compounds that can inhibit the activity of VEGFC and are exploring the potential of these compounds as treatments for cancer.

In addition to its potential as a drug target or biomarker, VEGFC is also of interest as a potential therapeutic target for other diseases. The researchers are exploring the potential of VEGFC as a target for neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. They are also considering using VEGFC as a target for other diseases, including cardiovascular disease and neurodegenerative disorders.

Overall, the discovery of VEGFC as a potential drug target or biomarker for cancer is a promising development in the field of genetics and could lead to new and effective treatments for this disease. The research being conducted by Dr. Liu and his team is being carried out in the hopes of finding new and better treatments for cancer and other diseases.

Protein Name: Vascular Endothelial Growth Factor C

Functions: Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors

The "VEGFC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VEGFC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets